Evolution of RAS Testing Over Time: Factors Influencing Mutation Rates in Metastatic Colorectal Cancer Patients
K Dufraing, C Keppens, V Tack, AG Siebers… - Colorectal …, 2020 - Taylor & Francis
Aim: Correct identification of RAS gene variants is key for targeted treatment decisions in
patients with metastatic colorectal cancer. Published RAS mutation rates differ and could be …
patients with metastatic colorectal cancer. Published RAS mutation rates differ and could be …
RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
A Boleij, V Tack, A Taylor, G Kafatos… - BMC cancer, 2016 - Springer
Background Treatment options for patients with metastatic colorectal cancer (mCRC) include
anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS …
anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS …
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
CY Chong, A Jalali, HL Wong, M Loft… - Asia‐Pacific Journal …, 2022 - Wiley Online Library
Background RAS mutation testing now routinely informs the optimal management of
metastatic colorectal cancer (mCRC), specifically the finding of a RAS mutation defines …
metastatic colorectal cancer (mCRC), specifically the finding of a RAS mutation defines …
RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data
G Kafatos, D Niepel, K Lowe… - Biomarkers in …, 2017 - Taylor & Francis
Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-
EGFR treatment for metastatic colorectal cancer. This noninterventional, observational …
EGFR treatment for metastatic colorectal cancer. This noninterventional, observational …
[HTML][HTML] The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective
U Malapelle, V Angerilli, F Pepe, G Fontanini… - Pathologica, 2023 - ncbi.nlm.nih.gov
RAS gene mutational status represents an imperative predictive biomarker to be tested in
the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the …
the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the …
RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014
A Lièvre, JL Merlin, JC Sabourin, P Artru, S Tong… - Digestive and Liver …, 2018 - Elsevier
Abstract Background RAS (NRAS+ KRAS) mutation testing is required in addition to simple
KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies …
KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies …
[HTML][HTML] RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
A Boleij, BBJ Tops, PDM Rombout, EM Dequeker… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract In 2013 the European Medicine Agency (EMA) restricted the indication for anti-
EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene …
EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene …
[HTML][HTML] Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled …
M Peeters, G Kafatos, A Taylor, VM Gastanaga… - European journal of …, 2015 - Elsevier
Background The use of epidermal growth factor receptor inhibitors to treat metastatic
colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS …
colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS …
Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database
G Kafatos, V Banks, P Burdon, D Neasham… - Future …, 2021 - Taylor & Francis
Background: The literature on biomarker testing for metastatic colorectal cancer (mCRC) in
Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five …
Europe is scarce. This study aimed to estimate the percentage of mCRC patients from five …
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
M Valladares-Ayerbes, MJ Safont… - Clinical and …, 2024 - Springer
Abstract Purpose RAS (KRAS/NRAS) mutational status on a tumor biopsy is mandatory to
guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS …
guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS …
相关搜索
- mutation rates ras testing
- cancer patients ras testing
- mutation rates cancer patients
- colorectal cancer ras braf
- colorectal adenocarcinoma ras testing
- colorectal cancer turnaround time
- ras braf turnaround time
- ras mutations pooled analysis
- ideal reporting ras testing
- pathology centers ras testing
- excellent reproducibility ras testing
- biomarker testing mutation prevalence
- ras mutations variation patterns
- colorectal cancer drastic reduction
- cancer patients oncology database
- cancer patients european countries